Boundless Bio
United States
51 articles about Boundless Bio
-
Boundless Bio Announces Upcoming Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/4/2023
Boundless Bio today announced two upcoming poster presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place from October 11-15, 2023, in Boston, MA.
-
Boundless Bio Appoints New Board Members and Establishes Clinical Advisory Board
10/2/2023
Boundless Bio today announced the appointment of two new members to its Board of Directors and the establishment of its Clinical Advisory Board.
-
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors
9/19/2023
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO ® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors.
-
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors
9/18/2023
Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Taiho Oncology to Evaluate LYTGOBI ® (futibatinib) in Combination with BBI-355 in Patients with FGFR Amplified Solid Tumors.
-
Boundless Bio Appoints Jami Rubin as Chief Financial Officer
7/31/2023
Boundless Bio, a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA for patients with oncogene amplified cancers, announced the appointment of Jami Rubin as Chief Financial Officer.
-
Boundless Bio to Present at the 2023 Jefferies Healthcare Conference
6/1/2023
Boundless Bio today announced that Chief Medical Officer, Klaus Wagner, M.D., Ph.D., will present at the 2023 Jefferies Healthcare Conference which will take place in New York City.
-
Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer
5/16/2023
Boundless Bio today announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital.
-
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-355 in Patients with Solid Tumors Harboring Oncogene Amplification
5/9/2023
Boundless Bio today announced that the first patient has been dosed with BBI-355 in a first-in-human, Phase 1/2 clinical trial for patients with locally advanced or metastatic solid tumors with oncogene amplifications (NCT05827614).
-
Boundless Bio Presents Data on the Novel Discovery of CHK1 as an Extrachromosomal DNA (ecDNA) Essential Target in Oncogene Amplified Cancers at the American Association for Cancer Research Annual Meeting 2023
4/17/2023
Boundless Bio today will present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.
-
Boundless Bio to Present at the Stifel 2023 Virtual Targeted Oncology Days
4/11/2023
Boundless Bio today announced that its President and Chief Executive Officer, Zachary Hornby, will present at the Stifel 2023 Virtual Targeted Oncology Days event which will take place virtually.
-
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2023
3/15/2023
Boundless Bio today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2023, held in Orlando and virtually from April 14-19, 2023.
-
Boundless Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
12/28/2022
Boundless Bio. announced that its Chief Executive Officer, Zachary Hornby, will present at the 41st Annual J.P. Morgan Healthcare Conference which will take place in San Francisco.
-
Boundless Bio to Participate at Two Upcoming Investor Conferences
11/15/2022
Boundless Bio today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences.
-
Celltrion agreed Wednesday to jointly develop Abpro’s cancer molecule ABP-102 in a deal that could net as much as $1.75 billion. See inside for more cancer collaborations.
-
Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges
6/16/2022
Boundless Bio is pleased to share the news that a global team of ecDNA experts comprised of several Boundless Bio scientific co-founders and led by Boundless Bio principal founder, Paul Mischel, M.D. has been awarded $25 million in funding by the National Cancer Institute and Cancer Research UK through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.
-
Boundless Bio to Present at the 2022 Jefferies Healthcare Conference
6/6/2022
Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Chief Executive Officer, Zachary Hornby, will present at the 2022 Jefferies Healthcare Conference, which will take place in New York City.
-
Boundless Bio Appoints Sara Weymer as Vice President, Clinical Operations
6/3/2022
Ms. Weymer has 20 years of clinical research and drug development experience in both biotech and CRO roles, comprising early to late-stage clinical development.
-
Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022
4/8/2022
Boundless Bio today will present a new finding at the American Association for Cancer Research (AACR) Annual Meeting.
-
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022
3/9/2022
Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022.
-
Boundless Bio to Present at the Oppenheimer 32nd Annual Healthcare Conference
3/8/2022
Boundless Bio announced that its Chief Executive Officer, Zachary Hornby, will present at the Oppenheimer 32nd Annual Healthcare Conference, which will take place virtually.